Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59 (4): 225-249. 10.3322/caac.20006.
Article
PubMed
Google Scholar
Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, Edwards BK: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001, 93 (11): 824-842. 10.1093/jnci/93.11.824.
Article
CAS
PubMed
Google Scholar
Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA: Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006, 107 (5): 1018-1022. 10.1097/01.AOG.0000210268.57527.a1.
Article
PubMed
Google Scholar
Moore DH: Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one?. Gynecol Oncol. 2009, 113 (3): 379-383. 10.1016/j.ygyno.2009.01.004.
Article
PubMed
Google Scholar
Ghurani GB, Penalver MA: An update on vulvar cancer. Am J Obstet Gynecol. 2001, 185 (2): 294-299. 10.1067/mob.2001.117401.
Article
CAS
PubMed
Google Scholar
Manchana T, Ittiwut C, Mutirangura A, Kavanagh JJ: Targeted therapies for rare gynaecological cancers. Lancet Oncol. 11 (7): 685-693.
Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell. 2007, 128 (4): 669-681. 10.1016/j.cell.2007.01.033.
Article
CAS
PubMed
Google Scholar
Jones PA, Baylin SB: The epigenomics of cancer. Cell. 2007, 128 (4): 683-692. 10.1016/j.cell.2007.01.029.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kouzarides T: Chromatin modifications and their function. Cell. 2007, 128 (4): 693-705. 10.1016/j.cell.2007.02.005.
Article
CAS
PubMed
Google Scholar
Glozak MA, Rogers MB: Retinoic acid- and bone morphogenetic protein 4-induced apoptosis in P19 embryonal carcinoma cells requires p27. Exp Cell Res. 2001, 268 (2): 128-138. 10.1006/excr.2001.5281.
Article
CAS
PubMed
Google Scholar
Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene. 2007, 26 (37): 5420-5432. 10.1038/sj.onc.1210610.
Article
CAS
PubMed
Google Scholar
Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004, 59 (2): 177-189. 10.1002/pros.20022.
Article
CAS
PubMed
Google Scholar
Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, et al: Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS. 2005, 113 (4): 264-268. 10.1111/j.1600-0463.2005.apm_04.x.
Article
CAS
PubMed
Google Scholar
Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC: Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005, 12 (4): 395-404. 10.1038/sj.cdd.4401567.
Article
CAS
PubMed
Google Scholar
Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H: Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther. 2006, 5 (9): 2203-2210. 10.1158/1535-7163.MCT-05-0480.
Article
CAS
PubMed
Google Scholar
Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, Haefner H, Neill S: Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005, 50 (11): 807-810.
PubMed
Google Scholar
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847. 10.1038/nm0798-844.
Article
CAS
PubMed
Google Scholar
Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T: Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int. 1998, 48 (8): 580-585. 10.1111/j.1440-1827.1998.tb03954.x.
Article
CAS
PubMed
Google Scholar
Santos M, Montagut C, Mellado B, Garcia A, Ramon y Cajal S, Cardesa A, Puig-Tintore LM, Ordi J: Immunohistochemical staining for p16 and p53 in premalignant and malignant epithelial lesions of the vulva. Int J Gynecol Pathol. 2004, 23 (3): 206-214. 10.1097/01.pgp.0000130108.03231.89.
Article
PubMed
Google Scholar
Riethdorf S, Neffen EF, Cviko A, Loning T, Crum CP, Riethdorf L: p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias. Hum Pathol. 2004, 35 (12): 1477-1483. 10.1016/j.humpath.2004.09.004.
Article
CAS
PubMed
Google Scholar
Santos M, Landolfi S, Olivella A, Lloveras B, Klaustermeier J, Suarez H, Alos L, Puig-Tintore LM, Campo E, Ordi J: p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am J Surg Pathol. 2006, 30 (11): 1347-1356. 10.1097/01.pas.0000213251.82940.bf.
Article
PubMed
Google Scholar
Biedermann K, Dandachi N, Trattner M, Vogl G, Doppelmayr H, More E, Staudach A, Dietze O, Hauser-Kronberger C: Comparison of real-time PCR signal-amplified in situ hybridization and conventional PCR for detection and quantification of human papillomavirus in archival cervical cancer tissue. J Clin Microbiol. 2004, 42 (8): 3758-3765. 10.1128/JCM.42.8.3758-3765.2004.
Article
CAS
PubMed
PubMed Central
Google Scholar
O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006, 13 (1): 8-15. 10.1097/01.pap.0000201828.92719.f3.
Article
PubMed
Google Scholar
Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000, 182 (3): 311-322. 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.
Article
CAS
PubMed
Google Scholar
Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9 (2): 139-148. 10.1016/S1470-2045(08)70004-4.
Article
CAS
PubMed
Google Scholar
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001, 1 (3): 194-202. 10.1038/35106079.
Article
CAS
PubMed
Google Scholar
Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008, 98 (3): 604-610. 10.1038/sj.bjc.6604199.
Article
CAS
PubMed
PubMed Central
Google Scholar
Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C: Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008, 14 (6): 1669-1677. 10.1158/1078-0432.CCR-07-0990.
Article
CAS
PubMed
Google Scholar
Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001, 61 (23): 8492-8497.
CAS
PubMed
Google Scholar
Imesch P, Fink D, Fedier A: Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril. 2010
Google Scholar
Li X, Chen BD: Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells. Am J Biomed Sci. 2009, 1 (4): 352-363.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K, Denk H: Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010, 9: 49-10.1186/1476-4598-9-49.
Article
PubMed
PubMed Central
Google Scholar
Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010, 3: 5-10.1186/1756-8722-3-5.
Article
PubMed
PubMed Central
Google Scholar
Kim J, Guan J, Chang I, Chen X, Han D, Wang CY: PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol Cancer Ther. 9 (7): 1977-1984.
Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q: Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol. 2007, 73 (12): 1901-1909. 10.1016/j.bcp.2007.03.009.
Article
CAS
PubMed
Google Scholar
Chung YL, Lee MY, Pui NN: Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis. 2009, 30 (8): 1387-1397. 10.1093/carcin/bgp079.
Article
CAS
PubMed
Google Scholar
Murakami J, Asaumi J, Kawai N, Tsujigiwa H, Yanagi Y, Nagatsuka H, Inoue T, Kokeguchi S, Kawasaki S, Kuroda M, et al: Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother Pharmacol. 2005, 56 (1): 22-28. 10.1007/s00280-004-0976-x.
Article
CAS
PubMed
Google Scholar